EBS Emergent BioSolutions Inc.

Emergent BioSolutions Announces Agreement to Settle Securities Class Action Litigation

Emergent BioSolutions Announces Agreement to Settle Securities Class Action Litigation

GAITHERSBURG, Md., Sept. 13, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) (“Emergent” or the “Company”) today announced that it has entered into an agreement to resolve the previously disclosed securities class action litigation pending in the United States District Court for the District of Maryland (In re Emergent BioSolutions Inc. Security Litigation, No. 8:21-cv-00955-DLB). This lawsuit was originally filed in 2021.

Under the terms of the proposed settlement, Emergent will pay $40 million, which will be substantially paid from insurance proceeds, to settle claims brought on behalf of stockholders who purchased Emergent’s common stock between March 10, 2020, and November 4, 2021. The proposed settlement, which is subject to court approval, includes no admission of liability or wrongdoing by Emergent or any current or former Emergent officers, directors or employees and will resolve all claims against the Company and other defendants in this matter.

“While Emergent believes that the legacy securities class action was without merit, we are pleased to have reached this agreement,” said Joe Papa, president and chief executive officer of Emergent. “Today’s announcement is a major step toward allowing us to move past this matter so we can continue focusing on our multiyear plan to turnaround and transform the business.”

About Emergent BioSolutions

At Emergent, our mission is to protect and enhance life. For 25 years, we’ve been at work defending people from things we hope will never happen—so we are prepared just in case they ever do. We provide solutions for complex and urgent public health threats through a portfolio of vaccines and therapeutics that we develop and manufacture for governments and consumers. We also offer a range of integrated contract development and manufacturing services for pharmaceutical and biotechnology customers. To learn more about how we plan to protect or enhance 1 billion lives by 2030, visit our and follow us on , , ,  and .

Safe Harbor Statement

This communication includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, including statements regarding the ability to obtain final court approval of the proposed settlement, the ability to satisfy the conditions of the proposed settlement, and the source of funds to be used to resolve these matters, are forward-looking statements. We generally identify forward-looking statements by using words like “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “forecast,” “future,” “goal,” “intend,” “may,” “plan,” “position,” “possible,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would,” and similar expressions or variations thereof, or the negative thereof, but these terms are not the exclusive means of identifying such statements. Forward-looking statements are based on our current intentions, beliefs and expectations regarding future events based on information that is currently available. We cannot guarantee that any forward-looking statement will be accurate. Readers should realize that if underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could differ materially from our expectations. Readers are, therefore, cautioned not to place undue reliance on any forward-looking statements. Any forward-looking statement speaks only as of the date of this communication and, except as required by law, we do not undertake any obligation to update any forward-looking statement to reflect new information, events or circumstances.

There are a number of important factors that could cause our actual results to differ materially from those indicated by any forward-looking statements. Readers should consider this cautionary statement, as well as the risk factors and other disclosures included in our periodic reports filed with the Securities and Exchange Commission, when evaluating our forward-looking statements.

Investor Contact:

Richard S. Lindahl

Executive Vice President, CFO

 

Media Contact:

Assal Hellmer

Vice President, Communications

 



EN
13/09/2024

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Emergent BioSolutions Inc.

Emergent Biosolutions Inc: 1 director

A director at Emergent Biosolutions Inc sold 25,000 shares at 10.910USD and the significance rating of the trade was 52/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two yea...

 PRESS RELEASE

Emergent BioSolutions Supports New Clinical Trial Evaluating the Safet...

Emergent BioSolutions Supports New Clinical Trial Evaluating the Safety and Efficacy of Brincidofovir in Treating Mpox Virus Across Africa PANTHER to conduct clinical trial under the leadership of Africa Centres for Disease Control and Prevention GAITHERSBURG, Md., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced that brincidofovir (brand name TEMBEXA®) will be included in a clinical trial conducted and sponsored by PANTHER, under the leadership of the Africa Centres for Disease Control and Prevention (Africa CDC), as part of the ‘MpOx Study in Afr...

 PRESS RELEASE

Emergent BioSolutions Reports Third Quarter 2024 Financial Results

Emergent BioSolutions Reports Third Quarter 2024 Financial Results Third Quarter 2024 Total Revenues of $293.8 million, increase of 9% versus prior yearThird Quarter 2024 Net Income of $114.8 million, increase of 144% versus prior yearThird Quarter 2024 Adjusted EBITDA of $105.3 million, increase of 432% versus prior yearRaises FY 2024 guidance GAITHERSBURG, Md., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today reported financial results for the third quarter ended September 30, 2024. "Through disciplined execution and steady, measurable progress, Emergent'...

 PRESS RELEASE

Emergent BioSolutions Appoints Dr. Simon Lowry as Chief Medical Office...

Emergent BioSolutions Appoints Dr. Simon Lowry as Chief Medical Officer and Head of Research and Development Executive Management Team appointments contribute to Emergent’s transformation and beyond, including promotion of Jessica Perl to General Counsel and Corporate Secretary GAITHERSBURG, Md., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS), a global company providing solutions that address public health threats and delivering life-extending products to market, today announced the appointment of Simon Lowry, M.D., as chief medical officer, head of research and...

 PRESS RELEASE

Emergent BioSolutions to Release Third Quarter 2024 Financial Results ...

Emergent BioSolutions to Release Third Quarter 2024 Financial Results and Conduct Conference Call on November 6, 2024 GAITHERSBURG, Md., Oct. 23, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Wednesday, November 6, 2024, at 5:00 pm eastern time to discuss the financial results for the third quarter of 2024, recent business developments, and financial outlook for full year 2024. Webcast & Conference Call InformationParticipants can access the conference call live via . To join via telephone, please use the following dial-in details: U.S. /...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch